Citigroup Inc. Reduces Position in Epizyme Inc (EPZM)

Citigroup Inc. reduced its position in shares of Epizyme Inc (NASDAQ:EPZM) by 80.3% in the 1st quarter, Holdings Channel reports. The firm owned 13,581 shares of the biopharmaceutical company’s stock after selling 55,323 shares during the quarter. Citigroup Inc.’s holdings in Epizyme were worth $241,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. New York State Common Retirement Fund lifted its holdings in Epizyme by 11.8% during the 1st quarter. New York State Common Retirement Fund now owns 52,100 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 5,500 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Epizyme by 1,748.9% during the 1st quarter. JPMorgan Chase & Co. now owns 195,412 shares of the biopharmaceutical company’s stock worth $3,469,000 after purchasing an additional 184,843 shares during the last quarter. Federated Investors Inc. PA lifted its holdings in Epizyme by 951.4% during the 1st quarter. Federated Investors Inc. PA now owns 25,223 shares of the biopharmaceutical company’s stock worth $448,000 after purchasing an additional 22,824 shares during the last quarter. Northern Trust Corp lifted its holdings in Epizyme by 0.6% during the 1st quarter. Northern Trust Corp now owns 580,898 shares of the biopharmaceutical company’s stock worth $10,311,000 after purchasing an additional 3,538 shares during the last quarter. Finally, Thrivent Financial for Lutherans acquired a new stake in Epizyme during the 1st quarter worth approximately $1,051,000. 85.22% of the stock is owned by institutional investors and hedge funds.

EPZM has been the subject of several research reports. ValuEngine cut Epizyme from a “sell” rating to a “strong sell” rating in a report on Monday, April 9th. BidaskClub cut Epizyme from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 3rd. Wedbush lifted their price objective on Epizyme from $20.00 to $25.00 in a report on Friday, May 18th. Leerink Swann set a $24.00 price objective on Epizyme and gave the company a “buy” rating in a report on Tuesday, April 24th. Finally, SunTrust Banks dropped their price objective on Epizyme to $20.00 and set a “hold” rating for the company in a report on Tuesday, April 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $23.00.

Shares of NASDAQ EPZM opened at $14.80 on Friday. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -6.79 and a beta of 2.09. Epizyme Inc has a fifty-two week low of $11.15 and a fifty-two week high of $21.40.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Tuesday, May 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.05. During the same period last year, the firm earned ($0.56) earnings per share. equities research analysts anticipate that Epizyme Inc will post -2.22 earnings per share for the current fiscal year.

About Epizyme

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Want to see what other hedge funds are holding EPZM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Epizyme Inc (NASDAQ:EPZM).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply